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Abstract  
Botulinum toxin A (BTX-A) is approved for treatment of different cholinergic hyperactivity 
disorders, and, recently, migraine headache. Although suggested to act only locally, novel 
observations demonstrated bilateral reduction of pain after unilateral toxin injection, and 
proposed retrograde axonal transport, presumably in sensory neurons. However, up to now, 
axonal transport of BTX-A from periphery to CNS was identified only in motoneurons, but 
with unknown significance.  
We assessed the effects of low doses of BTX-A injected into the rat whisker pad (3.5 U/kg) or 
into the sensory trigeminal ganglion (1 U/kg) on formalin-induced facial pain. Axonal 
transport was prevented by colchicine injection into the trigeminal ganglion (5 mM, 2 µl). To 
find the possible site of action of axonally transported BTX-A, we employed 
immunohistochemical labeling of BTX-A– truncated synaptosomal-associated protein 25 ( 
SNAP-25) in medullary dorsal horn of trigeminal nucleus caudalis after toxin injection into 
the whisker pad. 
Both peripheral and intraganglionic BTX-A reduce phase II of formalin-induced pain. 
Antinociceptive effect of BTX-A was prevented completely by colchicine. BTX-A–truncated 
SNAP-25 in medullary dorsal horn (spinal trigeminal nucleus) was evident 3 days following 
the peripheral treatment, even with low dose applied (3.5 U/kg).  
Presented data provide the first evidence that axonal transport of BTX-A, obligatory for its 
antinociceptive effects, occurs via sensory neurons and is directed to sensory nociceptive 
nuclei in the CNS. 
 
Keywords: axonal transport; botulinum toxin A; synaptosomal associated protein 25; 
antinociceptive activity; sensory neurons. 
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Abbreviations: BTX-A, botulinum toxin A; SNAP-25, synaptosomal-associated protein 25; 
i.g., intraganglionic (in trigeminal ganglion); SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis; CGRP, calcitonin gene-related peptide.  
 
 
Apart from its well known therapeutic use in muscular hyperactivity and certain autonomic 
disorders (Ward et al., 2006, Truong et al., 2009), botulinum toxin A (BTX-A) was recently 
registered for migraine treatment (Dodick et al., 2010). Besides migraine, its beneficial effects 
not associated with cholinergic neurotransmission were reported in cluster headache, 
neuropathic pain, joint pain, back pain, etc (Querama et al., 2010). It was suggested that BTX-
A, similarly to its activity in cholinergic neurons, inhibits the local neurotransmitter release 
from sensory nerve endings by peripheral SNAP-25 (Synaptosomal Associated Protein of 25 
kDa) cleavage (Cui et al., 2004; Aoki, 2005). 
Recent studies of rat “mirror pain” (muscular hyperalgesia) and polyneuropathy models 
(paclitaxel-induced polyneuropathy, diabetic neuropathy) demonstrated bilateral effects 
following unilateral BTX-A injection (Bach-Rojecky and Lacković, 2009; Favre-Guilmard et 
al., 2009; Bach-Rojecky et al., 2010). Obviously, such effects cannot be explained only by 
local action on the sensory nerve endings adjacent to the site of injection. Importantly, BTX-A 
effects were prevented by colchicine-induced blockage of axonal transport in the sciatic 
nerve, suggesting that retrograde axonal transport of BTX-A is necessary for its 
antinociceptive action (Bach-Rojecky and Lacković, 2009). However, neurons involved in 
axonal transport are unknown as well as the destination of transported BTX-A. So far, axonal 
transport of BTX-A from periphery to the CNS was demonstrated only in motoneurons 
(Antonucci et al., 2008), but with unknown functional significance. 
Aims of this study were to investigate a.) in which neurons does BTX-A axonal transport,  
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essential for its antinociceptive effects, take place, and b.) to locate the destination of axonally 
transported BTX-A. Therefore, we examined the effects of low doses of BTX-A injected into 
the whisker pad or trigeminal ganglion on formalin-induced orofacial pain, and used 
intraganglionic colchicine to prevent the axonal transport in trigeminal sensory neurons. To 
investigate the possible site of BTX-A antinociceptive action we employed immunolabeling 
of BTX-A-truncated SNAP-25 in trigeminal nucleus caudalis. 
 
 
1. EXPERIMENTAL PROCEDURES 
1.1 Animals 
Male Wistar rats (University of Zagreb School of Medicine, Croatia), weighing 300-400 g, 
kept on 12 h/12h light and dark cycle, were used in all experiments. The experiments were 
conducted according to the European Communities Council Directive (86/609/EEC) and 
recommendations of the International Association for the Study of Pain (Zimmerman, 1983). 
All efforts were made to reduce the number of animals used and to reduce their suffering. 
Animal procedures were approved by the Ethical Committee of University of Zagreb School 
of Medicine (permit No. 07-76/2005-43). 
 
1.2 BTX-A injections 
For peripheral administration, conscious, restrained rats were injected unilaterally with 30 µl 
of saline-diluted BTX-A 3.5 U/kg (Botox®, Allergan Inc., Irvine, CA, USA) into the whisker 
pad tissue using a 271/2-gauge needle. 3.5 U/kg dose was chosen based on previous 
experiments by Cui et al., (2004) and from our laboratory (Bach-Rojecky and Lacković 2005, 
Bach-Rojecky et al., 2005). For intraganglionic (i.g.) injections, animals were anesthetized 
with chloral hydrate (Sigma, St. Louis, MO, USA; 300 mg/kg i.p.). Trigeminal ganglion was 
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injected as described by Neubert et al. (2005). In brief, 0-10 µl Hamilton syringe needle 
(Hamilton Microliter #701, Hamilton, Switzerland) was inserted through the skin into the 
infraorbital foramen, which lies in the medial part of zygomatic process, and through the 
infraorbital canal and foramen rotundum directly into the trigeminal ganglion. Saline-diluted 
BTX-A (1 U/kg, 2 µl) was slowly injected into the ganglion. Dose of 1 U/kg was chosen 
based on preliminary experiments and on the dose needed for antinociceptive effect after 
intrathecal application (Bach-Rojecky et al., 2010). Site of injection was verified by injecting 
2 µl of methylene blue (Sigma, St. Louis, MO, USA) to 5 animals. The dye resided only in 
trigeminal ganglion.  
 
1.3 Behavioral testing 
Antinociceptive activity of BTX-A was assessed in a model of formalin-induced facial pain. 
Conscious rats were injected with 50 µl of saline-diluted 2.5% formalin (Kemika, Zagreb, 
Croatia) (0.92 % formaldehyde) into the whisker pad ipsilateral to BTX-A pretreatment and 
placed in transparent cages for observation (45 min). Observer was blind to the animal 
treatment (however, experienced observer could see slightly atonic rat whisker movement in 
BTX-A peripherally treated animals). The number of seconds of formalin-induced ipsilateral 
facial rubbing/grooming was measured in 3 min periods during phases I and II of formalin-
induced pain (Rabboison and Dallel, 2004). Phase I (0-12 min) represents the acute 
nociceptive pain characterized by direct stimulation of nerve endings with formalin, while 
phase II (12-45 min) is characterized by the release of inflammatory mediators and 
sensitization (Cui et al., 2004, Raboisson and Dallel, 2004).  
-For testing of peripherally applied BTX-A (3.5 U/kg), rats were divided in 3 groups (5-6 
animals per group): 1. saline (i.g) + saline peripherally, 2. saline (i.g.) + BTX-A peripherally, 
3. colchicine (i.g.) + BTX-A peripherally. 
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-For intraganglionic BTX-A testing (1U/kg), rats were divided into 5 groups (4-7 animals per 
group): 1. saline (i.g.), 2. BTX-A (i.g.) 1 day, 3. BTX-A (i.g.) 2 days, 4. colchicine (i.g.) + 
BTX-A (i.g.) 2 days, 5. colchicine (i.g.) + saline (i.g.) 2 days. 
Colchicine (Sigma, St. Louis, MO, USA)  was injected i.g. (2 µl), as described above, 24 h 
prior to second injection (BTX-A or saline), ipsilaterally. To reduce the number of animals 
used, effects of intraganglionic colchicine (colchicine + saline group) on formalin-induced 
pain were tested only in the experiment with intraganglionic BTX-A application. Rats were 
tested 3 days after peripheral BTX-A injection based on data of Antonucci et al. (2008) and 
our preliminary experiments, and 1 and 2 days after intraganglionic BTX-A injection. 
 
 
1.4 Characterization of the antibody specificity to BTX-A-cleaved SNAP-25 by Western 
blot 
The antibody used for immunohistochemical detection of BTX-A-cleaved SNAP-25 (a kind 
gift from Assist. Prof. Ornella Rossetto, University of Padua, Italy) was used previously in 
study from Antonucci et al. (2008). One of the questions to the authors, regarding the 
specificity of the antibody to cleaved SNAP-25, is the lack of controls to differentiate between 
cleaved and non-cleaved SNAP-25. Thus, using the similar protocol as Antonucci et al. 
(2008), we injected BTX-A (4 U/rat) in rat dorsal hippocampus. One day following the 
treatment rats were sacrificed and hippocampus excised. Protein isolation, SDS-PAGE and 
Western blots were performed as described previously (Antonucci et al., 2008, Constantin et 
al., 2005). To visualize cleaved SNAP-25, and then the total SNAP-25, two sequential 
Western blots were performed on the same membrane. Membranes were blocked and 
incubated firstly with rabbit anti-cleaved SNAP-25 (1:500) in blocking solution overnight at 
4°C, and then with goat-anti-rabbit HRP -conjugated secondary antibody (Biosource, 
Invitrogen, Carlsbad, CA, USA). After development in chemoluminescent (Super Signal West 
Femto, Pierce, Rockford,IL, USA) and visualization by ECL camera (Biorad, Hercules, CA, 
USA), membrane was washed and incubated with the mouse monoclonal antibody to total 
SNAP-25 (1:5000, overnight at 4°C). Antibody to total SNAP-25 (SMI-81, Sternberger 
Monoclonals, Baltimore, MD, USA) is well characterized and recognizes both intact and 
BTX-A-cleaved SNAP-25 (Jurasinski et al., 2001). Then, the membrane was incubated with 
goat anti-mouse secondary antibody (BD Pharmingen, San Diego, CA, USA) and visualized.  
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As shown in a Figure 1., cleaved SNAP-25 (approximately 24 kDa band) was visible only in 
BTX-A-treated hippocampus and positioned under non-cleaved SNAP-25 (25 kDa band). 
Figure 1 
 
1.5 Immunohistochemistry 
For the time-course experiment rats were injected into the whisker pad with 15 U/kg BTX-A, 
and sacrificed 1, 3, or 5 days after BTX-A injection. To access the BTX-A effects at different 
peripheral doses, rats were injected with 3.5 U/kg, 15 U/kg, and 30 U/kg into the whisker pad 
and sacrificed after 5 days. Doses were chosen based on study from Cui et al. (2004). Rats 
were deeply anesthetized using chloral hydrate (300 mg/kg, i.p.) and transcardially perfused 
with 250 ml saline, followed by 250 ml of fixative (4% paraformaldehyde (Sigma-Aldrich, St. 
Louis, MO, USA) in 0.01 M PBS, pH 7.4). Brainstems with upper cervical spinal cords were 
dissected and cryoprotected at 4ºC overnight in 15% sucrose in fixative, followed by 30 % 
sucrose in PBS the next day, until the tissue sank. Immunohistochemical protocol was similar 
to that previously described (Antonucci et al., 2008). 40 µm coronal sections (medullas caudal 
from obex and upper cervical spinal cords) were cut on a cryostat and collected for free 
floating in PBS. Sections were washed 3 x 5 minutes in 0.25% Triton X-100 in PBS (PBST), 
blocked in 10% normal goat serum (Monosan, Uden, Holland) (NGS) (1h) and incubated 
overnight at room temperature with 1:400 anti-BTX-A-cleaved SNAP-25 rabbit polyclonal 
antibody in 1% NGS. The next day, sections were washed, blocked with 1% NGS for 30 
minutes and further incubated with 1:400 goat anti-rabbit Alexa Fluor-555 ((Invitrogen, 
Carlsbad, CA, USA),), in the dark for 2h at room temperature. Sections were then washed 
with PBST, mounted on glass slides with anti-fading agent (FluoroGel, Electron Microscopy 
Sciences, Hatfield, PA, USA) and visualized with fluorescent microscope (Olympus BX51, 
Olympus, Tokyo, Japan) connected to digital camera (Olympus DP-70, Olympus, Tokyo, 
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Japan).  
To obtain high-resolution image of the whole section, parts of brainstem sections were 
photographed using 10x magnification, and subsequently connected using Microsoft Paint 
software. Images were processed for brightness and contrast using Adobe Photoshop 
software. 
 
1.6 Statistical analysis 
The results of orofacial formalin test were presented as mean ± S.E.M. Between-group 
differences were analyzed by the Newman-Keuls post hoc test. P<0.05 was considered 
significant. 
 
2 RESULTS 
2.1 BTX-A reduces formalin-induced orofacial pain: necessity of axonal transport in 
sensory neurons 
BTX-A had no significant antinociceptive effects during phase I of formalin-induced pain. 
However, peripheral BTX-A pretreatment (3.5 U/kg) significantly reduced the time of facial 
grooming during phase II of formalin induced pain (measured 3 days post BTX-A injection). 
Injection of colchicine (5 mM) into trigeminal ganglion abolished the effect of subsequently 
applied BTX-A (Figure 2).  
Intraganglionic BTX-A (1 U/kg) reduced the formalin-induced face grooming 2 days after the 
injection (Figure 3). Pain was not significantly reduced when BTX-A was applied i.g. 1 day 
before the formalin test. Intraganglionic pretreatment with 5 mM colchicine prevented the 
antinociceptive effect of intraganglionic BTX-A. Intraganglionic injection of colchicine (5 
mM) alone did not alter formalin-induced pain (Figure 3).  
Figure 2 
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Figure 3 
2.2 Central SNAP-25 cleavage in TNC after BTX-A peripheral application 
Following application of BTX-A into the rat whisker pad (15 U/kg), fiber-like cleaved SNAP-
25 immunoreactivity, apparently with varicosities, appeared in dorsal horn of ipsilateral TNC 
(Figures 4 and 5). Occurrence of truncated SNAP-25 in dorsal horn was evident starting on 
day 3 after the injection but not on day 1 (Figure 5 A). Truncated SNAP-25 in TNC also 
appeared at lower and higher peripheral doses (3.5 and 30 U/kg) (Figure 5B). We did not 
quantify the immunoreactivity, however, our impression was that 3.5 U/kg dose produces less 
intensive cleaved SNAP-25 immununofluorescence than higher doses (15 U/kg and 30 U/kg). 
Cleaved SNAP-25 was present throughout the rostro-caudal length of the TNC and confined 
to the middle part of the medullar dorsal horn coronal section (TNC according to rat brain 
atlas (Paxinos and Watson, 2005)). This is in accordance with the dorso-ventral somatotopic 
organization of spinal trigeminal nuclei, whose middle portion belongs to maxillary branch of 
trigeminal nerve, which innervates the whisker pad (Florence and Lakshman, 1995; Capra and 
Dessem, 1992). In some sections only few immunoreactive fiber-like structures were visible 
in contralateral dorsal horn. Some immunoreactivity was also observed inconsistently in C1 
upper cervical dorsal horn. 
Figure 4 
Figure 5 
 
3 Discussion  
Cleavage of SNAP-25 at neuromuscular junctions or autonomic synapses, induced by 
enzymatic activity of BTX-A light chain, results in blockade of acetylcholine (ACh) release. 
Analogous mechanism was proposed as an explanation of antinociceptive activity in 
peripheral sensory neurons (Cui et al., 2004; Aoki, 2005). In formalin-induced inflammatory 
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pain, peripheral BTX-A pretreatment had no effect on the acute nociceptive pain in phase I 
but it reduced pain during inflammatory phase II, accompanied by lowered peripheral 
glutamate release and reduction of edema in inflamed paw tissue. The most logical 
explanation was that both antinociceptive and anti-inflammatory actions of BTX-A are 
mediated by blockage of neurotransmitter and inflammatory mediator release from sensory 
nerve endings, as a consequence of peripheral SNAP-25 cleavage (Aoki, 2005). 
However, further studies with other inflammatory pain models showed dissociation between 
anti-inflammatory and antinociceptive activity of BTX-A. When applied in doses that 
effectively reduced pain, BTX-A had no effect on capsaicin-induced neurogenic inflammation 
and carrageenan-induced edema (Bach-Rojecky and Lacković, 2005; Bach-Rojecky et al., 
2007; Favre-Guilmard et al., 2009). Since inflammation is a peripheral phenomenon, the lack 
of the BTX-A effect on inflammation while concomitantly reducing pain brought into 
question the inhibition of peripheral exocytosis as a main mechanism of the antinociceptive 
action.  
 
3.1 Involvement of CNS and importance of axonal transport for BTX-A antinociceptive 
activity 
Evidence of antinociceptive activity distant from the site of peripheral unilateral BTX-A 
injection was found in paclitaxel- induced polyneuropathy  (Favre-Guilmard et al., 2009), 
acidic saline-induced muscular hyperalgesia (Bach-Rojecky and Lacković, 2009) , and 
diabetic neuropathy Bach-Rojecky et al., 2010). In those reports, apart from the injected side, 
BTX-A reduced the pain on contralateral side, too. Also, BTX-A injection into the distally cut 
sciatic nerve was still able to reduce contralateral pain in a model of bilateral muscular 
hyperalgesia, thus excluding the involvement of peripheral nerve endings (Bach-Rojecky and 
Lacković, 2009). In this model, effect of peripheral BTX-A was prevented by colchicine 
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injection into the sciatic nerve (Bach-Rojecky and Lacković, 2009). These observations 
demonstrated the necessity of retrograde axonal transport for BTX-A antinociceptive activity, 
and probably a central site of toxin’s action. In line with that, antinociceptive activity of BTX-
A is obtained with lower doses and with faster onset after intrathecal than after peripheral 
injection (Bach-Rojecky et al., 2010).  Recently, it was found that increased vesicular release 
from trigeminal ganglionic cells acutely isolated from rats with experimental trigeminal 
neuropathy was prevented if animals were pretreated with peripherally applied BTX-A 
(Kitamura et al., 2009). The authors suggested BTX-A retrograde transport from periphery 
and transcytosis within ganglionic somata as a possible explanation. Most recent studies of 
BTX-A effects on regenerative processes in sciatic nerve and neuroimmunological changes in 
dorsal root ganglia and lumbal dorsal horn of rats with experimental neuropathy also suggest 
the possible direct BTX-A action distant from the site of injection due to retrograde axonal 
transport (Marinelli et al., 2010, Mika et al., 2011, Pavone and Luvisetto, 2010).     
Observations described up to now suggest that antinociceptive action of BTX-A is centrally 
mediated and axonal transport-dependent. To verify the hypothesis that BTX-A is axonally 
transported through sensory neurons, in present experiments we investigated BTX-A effects 
in trigeminal sensory system. In a model of pain induced by formalin injection into the 
whisker pad, peripherally applied BTX-A (3.5 U/kg) reduced inflammatory phase II of 
formalin pain. Effects of peripheral BTX-A were completely abolished by colchicine injection 
into the trigeminal sensory ganglion (Figure 2).  Intraganglionic BTX-A in a dose of 1 U/kg in 
our experiment had similar effect like peripheral dose of 3.5 U/kg BTX-A. These observations 
confirm the assumption that in present experiments, axonal transport of BTX-A occurs via 
trigeminal sensory neurons and rules out the importance of axonal transport via motor or 
sympathetic neurons for antinociceptive effects of BTX-A.   
Since Kitamura et al. (2009) suggested blockage of vesicular release and BTX-A transcytosis 
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within ganglionic somata, we investigated whether BTX-A antinociceptive activity is caused 
by its actions inside the ganglion. We speculated that direct i.g. delivery of BTX-A would 
cause the spread of toxin within the ganglion and should enable fast antinociceptive effect. 
However, in the present experiment this action was delayed, occurring after 2 days, opening 
the possibility that the ganglion itself is not the main site of BTX-A antinociceptive activity. 
Moreover, by blocking axonal transport with colchicine pretreatment, effect of intraganglionic 
BTX-A was prevented (Figure 3), suggesting that BTX-A, even when delivered directly to the 
ganglion, still requires axonal transport to exert its antinociceptive effects. Thus, we 
hypothesized that BTX-A could be axonally transported, via sensory root, to trigeminal 
nociceptive projections in central nervous system.  
 
 
3.2 Occurrence of truncated SNAP -25 in the CNS after BTX-A injection in trigeminal 
innervation area 
To verify our assumption about the axonal transport of peripherally applied BTX-A to central 
trigeminal projections, we employed immunohistochemical labeling of truncated SNAP-25 in 
trigeminal nucleus caudalis (TNC), the region that predominantly receives facial nociceptive 
input. By demonstrating SNAP-25 cleavage in TNC we found that peripherally applied BTX-
A, or its catalytically active fragments, most probably reach central projections of primary 
sensory neurons by axonal transport (Figures 4 and 5). Time of occurrence of truncated 
SNAP-25 in our experiment (Figure 5A) is similar to the time course of BTX-A traffic in 
central neurons and motoneurons (Antonucci et al., 2008).  
Theoretically it might be possible that, instead of BTX-A, the truncated SNAP 25– product of 
its proteolytic activity, was axonally transported to central trigeminal nuclei. However, 
previously it was shown that BTX-A injection into the sciatic nerve, which was cut distally to 
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the place of toxin’s injection, still reduces pain on contralateral side (Bach-Rojecky and 
Lacković, 2009). This experiment rules out the possibility that cleaved SNAP-25, transported 
from peripheral nerve endings, would be involved in antinociceptive effects of BTX-A. 
Possibility of contribution of SNAP-25 cleavage in trigeminal ganglion cannot be ruled out 
completely. 
Confinement of cleaved SNAP-25 immunoreactivity to medullary dorsal horn excludes 
possible systemic spreading of BTX-A. Moreover, animals injected into whisker pad with 3.5 
and 15 U/kg did not exhibit impaired rotarod performance (results not shown). However, in 
some sections, few immunoreactive fiber-like structures were also visible in contralateral 
dorsal horns (data not shown), which could be associated with contralateral crossing of central 
afferent terminals (Jacquin et al., 1990). 
Occurrence of truncated SNAP-25 in TNC suggest that peripherally applied, axonally 
transported BTX-A can affect second order central sensory neurons, either presynaptically by 
SNAP-25 cleavage in central terminals of primary afferent neurons, or following transcytosis. 
Transcytosis of BTX-A to second-order synapses has been suggested in retinal ganglionic 
cells after axonal transport within visual system (Antonucci et al., 2008).  Recently Kitamura 
et al. (2009) on the basis of in vitro experiments proposed existence of BTX-A transcytosis in 
trigeminal ganglia, too.  
SNAP-25 cleavage in medullary dorsal horn (Figures 4 and 5) suggests that BTX-A can alter 
central nociceptive transmission of presently unknown neurotransmitters, which requires 
further investigation. There is evidence that, when applied directly to brainstem slices or 
intrathecally at the level of spinal cord, BTX-A alters release and expression of CGRP 
(Calcitonin gene related peptide), a neuropeptide involved in pain transmission (Meng et al., 
2009; Lee et al., 2010). 
Importantly, we found that BTX-A-truncated SNAP-25 appeared in TNC even at 3.5 U/kg, 
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the lowest peripheral antinociceptive dose (Bach-Rojecky et al., 2005, Bach-Rojecky and 
Lacković, 2005). Therefore, the axonal traffic of BTX-A from periphery to the CNS is not a 
phenomenon occurring only at high doses, as proposed by Alexiades –Armenakas (2008). 
Although comparison of doses in rats and humans can always be questioned, dose used in our 
experiment (3.5 U/kg) corresponds to 245 U dose in 70 kg human. BTX-A doses typically 
used in migraine treatment range from 100 to 260 U (Aurora et al., 2007), and in recent study 
which resulted in FDA approval for migraine treatment, from 155 to 195 U (Dodick et al., 
2010). 
 
4 Conclusion 
Antinociceptive effect of BTX-A requires axonal transport through sensory neurons and it is 
associated with occurrence of truncated SNAP-25 in central sensory nociceptive nuclei. 
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Figure 1. Characterization of specificity of polyclonal antibody to cleaved SNAP-25 
fragment. 
A) Western blot membrane processed with primary antibody to cleaved SNAP-25 (1:500 
dilution) and appropriate secondary antibody; B) the same membrane subsequently, before 
secondary antibody, incubated with antibody to total SNAP-25 (SMI-81, 1:5000 dilution) 
which recognizes both cleaved and intact SNAP-25; C) Separate experiment with the 
membranes incubated only with primary antibody to total SNAP-25 (the same as in 
experiment B) and appropriate secondary antibody. Control– hippocampus from saline-
injected animal; BTX– hippocampus injected with BTX-A 
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Figure 2. Effects of peripherally applied BTX-A on pain (facial rubbing) in first and second 
phase of orofacial formalin test and essential role of axonal transport.  
Facial pain was produced by formalin injection into the whisker pad (2.5% formalin, 50 µl). 
BTX-A (3.5 U/kg) was also applied into the whisker pad. Colchicine was injected into the 
trigeminal ganglion (5 mM, 2 µl) 24 h prior to BTX-A or saline injection into the whisker pad. 
Measurements were performed 3 days after BTX-A injection. i.g. – intraganglionic 
application into the trigeminal ganglion; periph – peripheral application into the whisker pad. 
Data are represented as mean ±SEM, n=5-6, * - P< 0.05 (Newman-Keuls post hoc). 
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Figure 3. Efects of intraganglionic BTX-A  on pain (facial rubbing) in first and second phase 
of orofacial formalin test and essential role of axonal transport.  
Facial pain was produced by formalin injection into the whisker pad (2.5% formalin, 50 µl). 
BTX-A (1U/kg) was injected into the trigeminal ganglion. Colchicine was also injected into 
the trigeminal ganglion (5 mM, 2 µl) 24 h before BTX-A or saline. Effect of BTX-A were 
measured on first and second day after the application.. BTX 1 day – BTX-A applied 1 day 
before the formalin test; BTX 2 days – BTX-A applied 2 days before the formalin test. Data 
are represented as mean ±SEM,  n=4-7, * = P< 0.05 (Newman-Keuls post hoc). 
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Figure 4. Immunofluorescently labeled truncated SNAP-25 (light red) in coronal sections of 
rat caudal medulla 5 days after BTX-A (15 U/kg) injection into the whisker pad.  
Contra=TNC contralateral to the site of injection. Ipsi= TNC ipsilateral to the site of injection; 
Section approx. 1.4 mm caudal from obex. Yellow scale bar, 500 µm (10x magnification); 
green scale bar, 100 µm (40x magnification). 
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Figure 5. Evidence of central enzymatic activity of BTX-A in ipsilateral TNC after peripheral 
application.  
A.) Time course: Occurrence of truncated SNAP-25 1, 3 and 5 days after BTX-A injection 
into the whisker pad (15 U/kg). B.) Effect of different doses: truncated SNAP-25 in ipsilateral 
TNC 5 days after peripheral BTX-A application at different doses (3.5, 15 and 30 U/kg). 
Sections approx. 1-1.5 mm caudal from obex. 40 x magnification; scale bar (gray line), 100 
µm. 
 
